B27. Horizon scanning - learnings from the past and defining a purpose and pathway for the future
Tracks
Reimbursement
| Thursday, June 13, 2024 |
| 4:30 PM - 5:30 PM |
| C3.2 |
Chair & Speakers
Dr Orin Chisholm
Program Director
The University Of Sydney
Chair: Horizon scanning - learnings from the past and defining a purpose and pathway for the future.
Abstract
This session will address horizon scanning of new and emerging health technologies and how to ensure the Australian health ecosystem is able to make use of horizon scanning to ensure it is able to adapt to incorporate these technologies (as seamlessly as posssible) into our federated system given the differing policy, governance, reimbursement, implementation and delivery settings. From 2003 to 2020 HealthPACT (and latterly the Health Technology Reference Group) was funded by federal, state and territory governments to undertake horizon scanning to identify new and emerging technologies that had the potential to impact patient access and health budgets, which resulted in impacts and outcomes hospital, health department and national policy, as well as to the private health system. The New Frontiers report and many submissions to the HTA Review have indicated the importance of horizon scanning to ensure health system readiness, but it's unclear what's required for HS2.0 in Australia in terms of governance, funding, operationalising, purpose, scope and health technology types. Is it for medicines alone, which is unlikely to benefit hospital systems, or should it be broader?
Biography
Orin is the program director for the postgraduate programs in Pharmaceutical and Medical Device Development at the University of Sydney. She has academic appointments with UNSW and Arizona State University, USA. Orin is on the Board of the Association of Graduate Regulatory Educators (USA) and is a founding member of the Regulatory Affairs Education Alliance. Orin received the TOPRA, UK award for excellence in regulatory education in 2017; became a Senior Fellow of the Higher Education Academy (UK) in 2018 and was elected a Fellow of the Regulatory Affairs Professionals Society in the USA in 2021. Her research focuses on regulatory science, workforce development and pharmaceutical policy.
Dr Paul Fennessy
Principal
Paul Fennessy Advisory
Horizon scanning - learnings from the past and defining a purpose and pathway for the future
Biography
Paul Fennessy has 35+ years experience in medical research, as an MSAC/PBAC evaluator, as Manager of the Genomics & Health Technology Unit in Victoria's Department of Health (VicDH) for 20 years and as Victoria's representative on various national committees, including for horizon scanning and genomics. He has policy, funding and implementation experience across national, state and hospital sectors. He proposed the development of the National Health Genomics Policy Framework, oversighted implementation of cell and gene therapies in Victoria and jointly developed the National Framework for assessing, funding and implementing highly specialised therapies and highly specialised services. Paul Fennessy Advisory was established early 2023 to assist stakeholders navigate the policy, funding and implementation space decisions focussed on expediting assessment, reimbursement and provision of new and emerging health technologies to patients.
Marty Hayes
Director
MAYES Healthcare
Horizon scanning - learnings from the past and defining a purpose and pathway for the future
Biography
As the Founder & Director of MAYES Healthcare PTY LTD, Martin brings extensive senior leadership experience demonstrating his knowledge, expertise, and skills in successfully leading new product market entry and launches, including execution and delivery. His roles as Senior Director ANZ and Commercial Operations and Capabilities Leader ANZ within large Pharma Companies, and with significant prior experience in the medical devices industry, shows his ability to drive revenue growth, exceed objectives, optimise team performance, and deliver outstanding value through strategic thinking and operational execution. As a former New Product Planning Manager in Market Access at Eli Lilly, he has successfully led the planning, cross-functional teamwork, and strategy development for new products, accelerating market access and driving innovation.
Clare Stuart
Policy and Advocacy Manager
Mito Foundation
Horizon scanning - learnings from the past and defining a purpose and pathway for the future
Biography
Clare Stuart’s younger sister Lizzie was born with both tuberous sclerosis and polycystic kidney disease. Clare’s experience as a sibling of someone with a rare genetic disease has led to her work over 25 years in the genetic and rare disease sector. She has a Masters in Public Health and has worked in policy development within the NSW Ministry of Health. Clare is the Policy and Advocacy Manager at Mito Foundation, driving improvements to health, disability and social support for people impacted by mitochondrial disease (mito). Her work includes advocating for increased investments and collaborations in research and therapeutic development for mito.
Ms Nicholette Conway
Director
Axis Health Co.
Horizon scanning - learnings from the past and defining a purpose and pathway for the future
Biography
With over 25 years of experience, Nicholette has worked in pharmaceuticals, medical devices, and diagnostics, with a commitment to equitable patient access to innovative treatments. She has worked with precision medicine and health tech startups, biotech and medtech scale-ups, and worked in major pharmaceutical companies including Eli Lilly, Amgen, MSD, and Bayer. Her expertise spans clinical development (Phase 1-3), Health Technology Assessment (HTA) new product planning (NPP), market access, and reimbursement (MSAC & PBAC), and she has successfully led commercial strategy, product development and implementation projects across oncology, rare diseases, infectious diseases, chronic disease, reproductive technologies, and genetics. Her approach is pragmatic and holistic, includes broad and diverse stakeholder engagement, and especially the inclusion of patients and their care givers to guide care. Nicholette is the current Board Chair of Genetic Alliance Australia and is passionate about enabling patient access to new technologies and precision medicine through multi-disciplinary collaboration.
